Occupier

Find Out The Latest

You can keep in touch with exciting developments for The Oxford Science Park and its occupiers here.

You can also keep up to date by following us on Twitter or LinkedIn

First production and administration of Axumin (fluciclovine (18F)) in France

12 Dec 2018

First production and administration of Axumin (fluciclovine (18F)) in France. Oxford, UK – December 12, 2018 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that the first commercial production of Axumin® (fluciclovine (18F)) in France occurred recently, with the first French patients being dosed. Axumin is a novel molecular imaging agent approved in the European Union for use in PET... Read more

Leading AI-driven drug discovery company Exscientia expands to The Oxford Science Park

01 Nov 2018

Facilities in The Schrödinger Building to bring together AI experts and biologists. Oxford, UK, 1 November 2018 – In a key point in its growth strategy, Exscientia, the innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is expanding its Oxford presence to the new Schrödinger Building on The Oxford Science Park, one of the UK’s leading parks for science and technology companies. In its new facilities,... Read more

Blue Earth Diagnostics wins prestigious ‘Best Emerging Biotech’ award

12 Oct 2018

Oxford, UK – October 12, 2018 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, has won the Oxford Bio Network (OBN) award for “Best Emerging Biotech ”. These prestigious OBN awards, which are judged by a panel of leading industry entrepreneurs and experts, celebrate innovation and outstanding achievement across the UK’s Life Sciences industry. The OBN’s “Best Emerging Biotech ” award goes... Read more

Blue Earth Diagnostics shortlisted for prestigious ‘Best Emerging Biotech Company’ award

09 Aug 2018

Oxford, UK – August 9, 2018 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, yesterday announced that it has been shortlisted as a finalist in the 2018 OBN awards in the category “Best Emerging Biotech Company”. These prestigious awards, which are judged by a panel of leading industry entrepreneurs and experts, celebrate innovation and outstanding achievement across the UK’s Life Sciences industry.... Read more

Evox Therapeutics expands into new facilities at The Oxford Science Park

26 Apr 2018

Thursday 26th April 2018 Expansion significantly increases laboratory space, creating new job opportunities in the area OXFORD, United Kingdom, 26 April 2018 – Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, announces that it has expanded into a new laboratory and office space at The Oxford Science Park, to enhance its research and development (R&D) capabilities and to facilitate growth of the... Read more

News